Epstein–Barr virus‐associated Hodgkin's lymphoma

@article{Gandhi2004EpsteinBarrVH,
  title={Epstein–Barr virus‐associated Hodgkin's lymphoma},
  author={Maher K. Gandhi and Judy T. Tellam and Rajiv Khanna},
  journal={British Journal of Haematology},
  year={2004},
  volume={125}
}
Survivors of Hodgkin's lymphoma (HL) frequently have many years to experience the long‐term toxicities of combined modality therapies. Also, a significant proportion of HL patients will relapse or have refractory disease, and less than half of these patients will respond to current salvage strategies. 30–50% of HL cases are Epstein–Barr virus associated (EBV‐positive HL). The virus is localized to the malignant cells and is clonal. EBV‐positive HL is more frequent in childhood, in older adults… Expand
EBV in Hodgkin Lymphoma
TLDR
Circulating EBV-DNA may serve as a biomarker to monitor response to therapy, and eventually, EBV will become a target for therapeutic intervention also in HL. Expand
Association between the Epstein-Barr Virus and Hodgkin’s Lymphoma in the North-Eastern Part of Hungary: Effects on Therapy and Survival
TLDR
EBV infection may be involved in the pathogenesis of HL in the Hungarian study cohort, but it does not significantly affect clinical symptoms, therapeutic results or complete and event-free survival of HL patients. Expand
Impact of the Epstein–Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea
TLDR
The presence of EBV in tumor cells is associated with adverse prognostic factors and EBV-positive HL is significantly associated with poorer DSS in all age groups. Expand
Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.
TLDR
A large series of patients with this disease provided additional evidence that this neoplasia, with a median age of onset of 71 years, has the highest incidence in elderly patients aged >50 years, suggesting that this disease may be related to the immunological deterioration that occurs during the aging process. Expand
Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study.
  • T. Keegan, S. Glaser, +6 authors R. Ambinder
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors, according to age, sex, and histologic subtype. Expand
Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma?
TLDR
Not only did WB EBV-DNA positive patients show significantly higher levels of antibody titers against EBV, but positive associations with Hepatitis C virus serology and age were also observed, which suggests heightened host immune compromise in WB EBVs positive patients and is consistent with emerging evidence of the importance of host immunity as a prognostic indicator. Expand
Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas
TLDR
T cells specific for the weakly immunogenic latent membrane protein 2 have been expanded ex vivo and have promoted tumor regression in a subset of patients and another potential therapeutic strategy could be to try to induce lytic EBV infection in the tumor cells. Expand
Age‐related Epstein–Barr virus‐associated B‐cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease
TLDR
The aim of the present review is to briefly summarize the overall clinicopathological profile of this newly recognized age‐related EBV+ B‐LPD andEBV+ Hodgkin lymphoma for a practical diagnostic approach. Expand
Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly
TLDR
EBV+ DLBCL of the elderly is highly aggressive with a median survival of 2 years, and patients are less responsive to standard chemotherapy compared with other B-LPD, and differential diagnoses include EBV+ B- LPD, classical Hodgkin lymphoma and EBV–DLBCL. Expand
Spectrum of Epstein-Barr virus-related diseases: a pictorial review
TLDR
The spectrum of EBV-related lymphoproliferative disorders and lymphomas are especially common in immunocompromised patients and awareness of their clinical settings and imaging spectrum contributes to early detection and early treatment of possibly life-threatening disorders. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 169 REFERENCES
Viruses and Hodgkin's lymphoma.
  • R. Jarrett
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002
TLDR
It is suggested that Hodgkin's lymphoma can be divided into four entities on the basis of EBV status and age at presentation, with three groups ofEBV-associated cases and a single group of EBv-negative cases. Expand
Epstein-Barr virus and hodgkin’s disease
  • L. Weiss
  • Medicine
  • Current oncology reports
  • 2000
TLDR
EBV-latent antigens may represent a target for possible immune therapy in Hodgkin’s disease by the activation of anti-apoptotic factors in a premalignant germinal center B-lymphocyte. Expand
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
TLDR
LMP2-specific CTL were successfully generated from individuals who were EBV-seronegative or who were non-responsive to LMP2 when presented on autologous LCL, using both retrovirus and herpesvirus vectors to express L MP2 in dendritic cells. Expand
Epstein‐Barr virus‐associated Hodgkin's disease: Epidemiologic characteristics in international data
TLDR
It is suggested that age, sex, ethnicity and the physiologic effects of poverty may represent biologic modifiers of the EBV association and confirmed that this association is strongly but variably linked to histologic subtype. Expand
Disappearance of the Epstein–Barr virus in a relapse of Hodgkin's disease
TLDR
A case of nodular sclerosing HD of the B‐cell type that was associated with EBV in the initial manifestation, but was found to be EBV‐negative in the relapse of the tumour, implies that in a given individual EBV can be lost from malignant tumours and therefore shows that the EBV infection is not required to maintain neoplastic growth of HD tumour cells. Expand
Variation in the frequency of Epstein–Barr virus-associated Hodgkin's disease with age
TLDR
The results do not generally support the ‘three disease’ model, and when females were analysed separately, older women (45+ years) were significantly more likely to have EBV-positive disease than their younger counterparts (<45 years). Expand
Assessment of the prognostic impact of the Epstein–Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease
TLDR
It is concluded that expression of LMP1 in HRS cells has a favourable impact on prognosis for HD patients, but that this effect may be restricted to young adult patients and those with early stage disease. Expand
Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed‐Sternberg cells of patients with Hodgkin's disease
TLDR
There did not appear to be any relationship between EBV serology or the presence of EBV in HRS cells and clinical outcome, and the relationship between antibody titers reactive with different EBV antigens remained unclear. Expand
Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States.
TLDR
The hypothesis that EBV contributes to the pathogenesis of HD in children, particularly in mixed cellularity HD, is supported and the possibility that there are important geographic, racial, or ethnic factors in the EBV association with HD is raised. Expand
Hodgkin lymphoma and Epstein‐Barr virus (EBV): No evidence to support hit‐and‐run mechanism in cases classified as non‐EBV‐associated
TLDR
No evidence is found to support the idea that a hit‐and‐run mechanism involving EBV plays a role in the pathogenesis of HL, and additional studies clearly showed that some HL patients have never been infected by EBV. Expand
...
1
2
3
4
5
...